OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) shares were down 13.7% during trading on Tuesday . The stock traded as low as $2.13 and last traded at $2.21. Approximately 201,376 shares traded hands during trading, an increase of 41% from the average daily volume of 143,002 shares. The stock had previously closed at $2.56.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of OKYO Pharma in a research report on Monday, May 5th.
Check Out Our Latest Analysis on OKYO
OKYO Pharma Stock Up 5.3%
The company has a 50 day moving average price of $1.71 and a 200 day moving average price of $1.35.
Hedge Funds Weigh In On OKYO Pharma
An institutional investor recently bought a new position in OKYO Pharma stock. Dauntless Investment Group LLC bought a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,988,780 shares of the company's stock, valued at approximately $2,526,000. OKYO Pharma makes up approximately 3.0% of Dauntless Investment Group LLC's portfolio, making the stock its 2nd largest position. Dauntless Investment Group LLC owned about 5.88% of OKYO Pharma at the end of the most recent quarter. Institutional investors own 2.97% of the company's stock.
OKYO Pharma Company Profile
(
Get Free Report)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Featured Stories
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
